FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

[cafead]

via Merck and Samsung Bioepis clinched the FDA’s endorsement of their Humira biosimilar, Hadlima, adding a key market to the list of countries where they have gained approval.

Now they just have to count down to the launch date negotiated with AbbVie: June 30, 2023.

article source